3 Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks With a Strong Future Roadmap: Shilpa Medicare, Viyash Scientific and Medplus Health Services
- October 14, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Shilpa Medicare Rs 973.60, P/E 67.52. Viyash Scientific Rs 235.02, P/E 39.01. Medplus Rs 617.00, P/E 36.06. Closing prices of 13 Oct 2026.
Quick Answer
Biologics maker, specialty ingredient and pharmacy retail stocks with the clearest long-term roadmaps today include Shilpa Medicare in active ingredients, formulations, biologics and contract manufacturing, Viyash Scientific in active pharmaceutical ingredients, formulations and contract manufacturing and Medplus in a pharmacy retail chain with a growing private label range, mainly in southern India. FY26 revenue growth was 18.2% at Shilpa Medicare, 14.0% at Viyash Scientific and 12.6% at Medplus. P/E stands at 67.52 for Shilpa Medicare (industry 37.59), 39.01 for Viyash Scientific (industry 37.59) and 36.06 for Medplus (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Biologics maker, specialty ingredient and pharmacy retail stocks give investors exposure to medicines and pharmacy services that doctors, drug makers and patients rely on. Contract orders, ingredient volumes and store growth decide how much of that demand turns into profit.
This list covers three biologics maker, specialty ingredient and pharmacy retail stocks: Shilpa Medicare for active ingredients, formulations, biologics and contract manufacturing, Viyash Scientific for active pharmaceutical ingredients, formulations and contract manufacturing and Medplus Health Services for a pharmacy retail chain with a growing private label range, mainly in southern India. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks?
Biologics maker, specialty ingredient and pharmacy retail stocks are shares of companies that make biologics, supply ingredients or run pharmacies. Results depend on contract orders, ingredient volumes and store growth, so growth and margins separate the stronger names.
Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three biologics maker, specialty ingredient and pharmacy retail stocks as of the 13 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Shilpa Medicare | 973.60 | 20,072 | 67.52 | 37.59 | 9.39% | 0.25 |
| Viyash Scientific | 235.02 | 10,422 | 39.01 | 37.59 | 7.07% | 0.17 |
| Medplus Health Services | 617.00 | 7,589 | 36.06 | 66.59 | 11.12% | 0.72 |
Among healthcare stocks, Shilpa Medicare and Viyash Scientific trade at a premium to the industry P/E, while Medplus trades at a discount.
Why Do Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks Have a Strong Roadmap in India?
Biologics maker, specialty ingredient and pharmacy retail stocks have a strong roadmap in India because health spending, drug outsourcing and organised pharmacy growth keep lifting these healthcare firms. Three drivers stand out.
- Advanced medicines: Biologics and contract work add higher-value revenue.
- Ingredient demand: Drug makers source active ingredients and formulations.
- Organised pharmacy: Chain stores gain from private label growth.
Shilpa Medicare: Ingredients, Biologics and Formulations Anchor the Roadmap
Shilpa Medicare’s roadmap rests on active ingredients, formulations, biologics and contract development and manufacturing, with a wide product mix supporting revenue.
Revenue grew from Rs 1,159.77 crore in FY22 to Rs 1,548.71 crore in FY26, a 33.5% rise, and FY26 revenue was 18.2% higher than FY25. FY26 net profit was Rs 243.33 crore. In Q1 FY27, revenue grew 43.0% to Rs 468.91 crore. Operating margin was 30.79% in FY26 and 31.21% in Q1 FY27 against 30.26% a year earlier.
Debt to equity is 0.25 and return on equity is 9.39%. FY26 operating cash flow was Rs 342.18 crore against capital expenditure of Rs 370.63 crore. Shilpa Medicare paid a dividend of Rs 0.6 per share for FY26, a yield of 0.06%. At a P/E of 67.52 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 67.52 sits above the industry P/E of 37.59, so earnings delivery matters for the valuation.
Viyash Scientific: Ingredients for Human and Animal Health Drive the Pipeline
Viyash Scientific’s roadmap rests on active ingredients for human and animal health and related development services, with a wider ingredient basket supporting revenue.
Revenue grew from Rs 1,423.66 crore in FY22 to Rs 3,463.86 crore in FY26, a 143.3% rise, and FY26 revenue was 14.0% higher than FY25. FY26 net profit was Rs 224.65 crore. In Q1 FY27, revenue grew 19.6% to Rs 954.67 crore. Operating margin was 20.21% in FY26 and 19.73% in Q1 FY27 against 15.71% a year earlier.
Debt to equity is 0.17 and return on equity is 7.07%. FY26 operating cash flow was Rs 322.91 crore against capital expenditure of Rs 134.72 crore. At a P/E of 39.01 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: Return on equity of 7.07% is modest.
Medplus Health Services: Pharmacy Retail Stores Anchor the Roadmap
Medplus’ roadmap rests on a pharmacy retail chain with stores across several states, with store expansion supporting revenue.
Revenue grew from Rs 3,810.64 crore in FY22 to Rs 6,963.79 crore in FY26, an 82.7% rise, and FY26 revenue was 12.6% higher than FY25. FY26 net profit rose 46.2% to Rs 219.61 crore. Over four years, net profit rose from Rs 94.72 crore in FY22 to Rs 219.61 crore. In Q1 FY27, revenue grew 21.9% to Rs 1,899.43 crore. Operating margin was 9.85% in FY26.
Debt to equity is 0.72 and return on equity is 11.12%. FY26 operating cash flow was Rs 495.58 crore against capital expenditure of Rs 123.03 crore. At a P/E of 36.06 against an industry P/E of 66.59, the stock trades below its industry multiple.
What to watch: Net profit margin is only 3.2%, so small cost changes move earnings.
Best Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks in India: Shilpa Medicare vs Viyash Scientific vs Medplus on Key Financials
Among the best biologics maker, specialty ingredient and pharmacy retail stocks in India, Shilpa Medicare leads on FY26 revenue growth and FY26 operating margin; Viyash Scientific leads on the lowest debt to equity; Medplus leads on return on equity and the lowest P/E. The table puts the numbers side by side.
| Metric | Shilpa Medicare | Viyash Scientific | Medplus |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 1,548.71 | 3,463.86 | 6,963.79 |
| FY26 revenue growth | 18.2% | 14.0% | 12.6% |
| FY26 net profit (Rs Cr) | 243.33 | 224.65 | 219.61 |
| FY26 operating profit margin | 30.79% | 20.21% | 9.85% |
| Q1 FY27 revenue growth (YoY) | 43.0% | 19.6% | 21.9% |
| Return on equity | 9.39% | 7.07% | 11.12% |
| P/E ratio | 67.52 | 39.01 | 36.06 |
| Debt to equity | 0.25 | 0.17 | 0.72 |
| Dividend yield | 0.06% | 0.00% | 0.00% |
| FY26 operating cash flow (Rs Cr) | 342.18 | 322.91 | 495.58 |
Healthcare earnings follow contract orders, ingredient volumes and store growth, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen biologics maker, specialty ingredient and pharmacy retail stocks and shortlist biologics maker, specialty ingredient and pharmacy retail stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and return on equity together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks
- Valuation: Shilpa Medicare trades at 67.52 times earnings against an industry multiple of 37.59.
- Pricing rules: Price controls can affect margins.
- Competition: Rival brands and providers can pressure growth.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Shilpa Medicare, Viyash Scientific and Medplus live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare stocks cover biologics, specialty ingredients and pharmacy retail. Shilpa Medicare leads on FY26 revenue growth and FY26 operating margin; Viyash Scientific leads on the lowest debt to equity; Medplus leads on return on equity and the lowest P/E.
Across biologics maker, specialty ingredient and pharmacy retail stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the biologics maker, specialty ingredient and pharmacy retail stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks
Which are the best biologics maker, specialty ingredient and pharmacy retail stocks in India with a strong roadmap?
Ans. Shilpa Medicare, Viyash Scientific and Medplus Health Services stand out for their roadmaps in biologics, specialty ingredients and pharmacy retail. FY26 revenue growth was 18.2% at Shilpa Medicare, 14.0% at Viyash Scientific and 12.6% at Medplus, and return on equity ranges from 7.07% to 11.12%.
Is Shilpa Medicare a good stock to buy now?
Ans. Shilpa Medicare has a debt to equity ratio of 0.25, a return on equity of 9.39% and a P/E of 67.52 against an industry P/E of 37.59. Valuation, growth and pricing rules move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Shilpa Medicare, Viyash Scientific and Medplus?
Ans. The P/E ratio is 67.52 for Shilpa Medicare (industry 37.59), 39.01 for Viyash Scientific (industry 37.59) and 36.06 for Medplus (industry 66.59). Only Shilpa Medicare and Viyash Scientific trade at or above the industry multiple.
Which of these biologics maker, specialty ingredient and pharmacy retail stocks has the highest return on equity?
Ans. Medplus Health Services has the highest return on equity at 11.12%, followed by Shilpa Medicare at 9.39% and Viyash Scientific at 7.07%.
What are the risks of investing in biologics maker, specialty ingredient and pharmacy retail stocks?
Ans. The main risks are valuation, pricing rules, competition and quarterly trends. Shilpa Medicare trades at 67.52 times earnings against an industry multiple of 37.59.
How did Shilpa Medicare, Viyash Scientific and Medplus perform in Q1 FY27?
Ans. Shilpa Medicare reported revenue of Rs 468.91 crore, up 43.0% year on year. Viyash Scientific reported revenue of Rs 954.67 crore, up 19.6% year on year. Medplus Health Services reported revenue of Rs 1,899.43 crore, up 21.9% year on year.
Do biologics maker, specialty ingredient and pharmacy retail stocks pay dividends?
Ans. Shilpa Medicare pays dividends. The dividend yield is 0.06% for Shilpa Medicare, based on dividends declared for FY26.
How can I invest in biologics maker, specialty ingredient and pharmacy retail stocks in India?
Ans. You can buy biologics maker, specialty ingredient and pharmacy retail stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
